All In MedTech

Device Trial Radar · NCT01757444

Non Invasive Ventilation : Efficacy of a New Ventilatory Mode in Patients With OHS

Clinical Benefits and Tolerance to a New Ventilatory Mode in Patients With Obesity Hypoventilation Syndrome (OHS).

Last checked: Nov 19, 2026Latest source record: Sep 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Jun 2013

Primary completion

Sep 2018

Study completion Sep 2018

Sponsor

Sponsor type
Academic, hospital or other
First posted
Dec 31, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In 2012, it has announced the availability of the new ventilator (BiPAP- A40), which could offer potential advantages over fixed level pressure support, in particular, in patients with obesity hypoventilation syndrome (OHS). One of the key benefits of the BiPAP A40 is an innovative ventilation mode called AVAPS-AE, which automatically maintains airway patency while delivering the correct level of ventilation each user requires, whatever their body position or sleep stage. AVAPS-AE mode is also aimed to help the clinicians during the initial titration of therapy, while providing long term comfort and assuring therapy compliance. However, studies on the physiologic and clinical effects have not yet been performed. The aim of our singled-blind randomised multicentre controlled trial is to prospectively investigate the effects of BiPAP with the spontaneous/timed (S/T) or the AVAPS-AE ventilation mode over 8 weeks on sleep quality, ventilation pattern, gas exchange, symptoms, body composition, level of physical activity and health-related quality of life in OHS patients.

Conditions

  • Obesity Hypoventilation Syndrome

Interventions

  • BiPAP - A40Device

    Patients receiving BiPAP AVAPS - AE ventilatory mode at home

  • BiPAP - STDevice

    Patients receiving BiPAP- ST mode at home.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CHANGE IN SLEEP QUALITYTime frame: Day 1 and Day 61

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire d'Angers

    Angers, France

  • Centre Hospitalier de Béziers

    Béziers, France

  • Hôpital Haut- Lévêque

    Bordeaux, France

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.